Therefore, this study aims to investigate the therapeutic potential of a vaccine using long multi-epitope peptides composed of MHCI (BIRC5 and EphA2) and MHCII peptides (PADRE) in combination with lenalidomide and anti-PD1 to enhance CTLs function against GBM in a mouse model. This evidence concerns the gene EPHA2 and glioblastoma.